Chemotherapy-associated steatohepatitis induced by irinotecan: A novel animal model

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 4, 2014, Pages 711-720

  Costa, Marcelo Leite Vieira ^a,b   Lima, Roberto César Pereira ^a   Aragão, Karoline Sabóia ^a   Medeiros, Raul Pinheiro ^a   Marques Neto, Raphael Dias ^a   De Sá Grassi, Lucas ^a   Leite, Leandro Linhares ^a   Nunes, Lorena Guimaraes ^a   De Mesquita Neto, José Wilson Benevides ^b   De Castro Brito, Gerly Anne ^a   De Souza, Marcellus Henrique Loiola Pontes ^a   De Almeida, Paulo Roberto Carvalho ^a   Ribeiro, Ronaldo Albuquerque ^a,b  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b Instituto do Cancer do Ceara   (Brazil)

Author keywords

Animal model; Irinotecan; Liver; Steatohepatitis; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CAMPTOTHECIN; INTERLEUKIN 1BETA; IRINOTECAN; PEROXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; FATTY LIVER; HUMAN; LIVER; MALE; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; TIME; WEIGHT REDUCTION;

ALANINE TRANSAMINASE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASPARTATE AMINOTRANSFERASES; CAMPTOTHECIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FATTY LIVER; HUMANS; INTERLEUKIN-1BETA; LIVER; MALE; MICE; PEROXIDASE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT LOSS;

EID: 84925546107     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2434-8     Document Type: Article

References (30)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434-438
2. Mulhall BP, Ong JP, Younossi ZM (2002) Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 17:1136-1143
3. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467-2474
4. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:1413-1419
5. Kleiner DE, Brunt EM, Natta MV, Behling C, Contos MJ, Cummings OW et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-1321
6. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065-2072
7. Robinson SM, Wilson CH, Burt AD, Manas DM, White SA (2012) Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol. doi:10.1245/s10434-012-2438-8
8. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343(13):904-914
9. House MG, Ito H, Gonnen M, Fong Y, Allen PJ, DeMatteo RP et al (2010) Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1600 patients during two decades at a single institution. J Am Coll Surg 210(5):744-752
10. Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D et al (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509-522
11. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D et al (2004) Rescue surgery for unresectable colorectal liver metastasis downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644-657
12. Zorzi D, Laurent A, Pawlick TM, Lauwers GY, Vauthey JN, Abdalla EK (2007) Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastasis. Br J Surg 94:274-286
13. Hammond JS, Guha IN, Beckingham IJ, Lobo DN (2011) Prediction, prevention and management of postresection liver failure. Br J Surg 98:1188-1200
14. Day CP, Jame OF (1998) Steatohepatitis: a tale of two 'hits'? Gatroenterology 114:842-845
15. Melo ML, Brito GA, Soares RC, Carvalho SB, Silva JV, Soares PM et al (2008) Role of cytokines (TNF-α, IL-1β and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemother Pharmacol 61(5):775-784
16. Bradley PP, Christensen RD, Rothstein G (1982) Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood 60:618-622
17. Bligh EG, Dyer WJ (1959) A rapid method for total lipid extraction and purification. Can J Biochem Physiol 37:911-917
18. Hsu SM, Raine L (1981) Protein A, avidin and biotin in immunohistochemistry. J Histochem Cytochem 29:1349-1353
19. Fulco RA, Costa RC, Germano MP, Torre EA, Viscomi MG, Salimbeni V et al (2000) Hepatotoxicity of camptothecin derivatives in a primary culture system of rat hepatocytes. J Chemother 12(4):345-351
20. Keizman D, Maimon N, Ish-Shalom M, Buchbut D, Inbar M, Klein B et al (2010) An animal model for chemotherapy-associated steatohepatitis and its prevention by the oral administration of fatty acid bile acid conjugate. Cancer 116(1):251-255
21. Mikalauskas S, Mikalauskiene L, Bruns H, Nickkholgh A, Hoffmann K, Longerich T et al (2011) Dietary glycine protects from chemotherapy-induced hepatotoxicity. Amino Acids 40(4):1139-1150
22. Rasheed AZ, Rubin AH (2008) Toposiomerase-interactiona agents. In: DeVita VT, Lawrence TS, Rosenberg SA (eds) Devita, Hellman & Rosenberg's cancer: principles & practice of oncology, 8th edn. Lippincott Williams & Wilkins, Philadelphia, pp 439-440
23. Tilg H, Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52:1836-1846
24. Dinarello CA (2000) Proinflammatory cytokines. Chest 118:503-508
25. Valles SL, Blanco AM, Azorin I, Guasch R, Pascual M, Gomez-Lechon MJ et al (2003) Chronic ethanol consumption enhances interleukin-1 mediated signal transduction in rat liver and in cultured hepatocytes. Alcohol Clin Exp Res 27(12):1979-1986
26. Garcia-Monzon C, Martin-Perez E, Iacono OL, Fernández-Bermejo M, Majano PL, Apolinario A et al (2000) Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 33:716-724
27. Ha SK (2010) CHAE C. Inducible nitric oxide distribution in the fatty liver of a mouse with high fat diet induced obesity. Exp Anim 59(5):595-604
28. Geller DA, Nussler AK, Di Silvio M, Lowenstein CJ, Shapiro RA, Wang SC et al (1993) Cytokines, endotoxin and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci 90:522-526
29. Uslusoy HS, Nak SG, Gulten M (2011) Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis. World J Hepatol 3(8):219-227
30. Kleiner DE, Brunt EM (2012) Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 32:2-13